Literature DB >> 29229429

Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.

M J E Brill1, A N Kristoffersson1, C Zhao1, E I Nielsen1, L E Friberg2.   

Abstract

BACKGROUND: Deriving suitable dosing regimens for antibiotic combination therapy poses several challenges as the drug interaction can be highly complex, the traditional pharmacokinetic-pharmacodynamic (PKPD) index methodology cannot be applied straightforwardly, and exploring all possible dose combinations is unfeasible. Therefore, semi-mechanistic PKPD models developed based on in vitro single and combination experiments can be valuable to suggest suitable combination dosing regimens. AIMS: To outline how the interaction between two antibiotics has been characterized in semi-mechanistic PKPD models. We also explain how such models can be applied to support dosing regimens and design future studies. SOURCES: PubMed search for published semi-mechanistic PKPD models of antibiotic drug combinations. CONTENT: Thirteen publications were identified where ten had applied subpopulation synergy to characterize the combined effect, i.e. independent killing rates for each drug and bacterial subpopulation. We report the various types of interaction functions that have been used to describe the combined drug effects and that characterized potential deviations from additivity under the PKPD model. Simulations from the models had commonly been performed to compare single versus combined dosing regimens and/or to propose improved dosing regimens. IMPLICATIONS: Semi-mechanistic PKPD models allow for integration of knowledge on the interaction between antibiotics for various PK and PD profiles, and can account for associated variability within the population as well as parameter uncertainty. Decisions on suitable combination regimens can thereby be facilitated. We find the application of semi-mechanistic PKPD models to be essential for efficient development of antibiotic combination regimens that optimize bacterial killing and/or suppress resistance development.
Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotics; Drug combinations; Interaction; Semi-mechanistic pharmacokinetic–pharmacodynamic modelling; Simulations

Mesh:

Substances:

Year:  2017        PMID: 29229429     DOI: 10.1016/j.cmi.2017.11.023

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  15 in total

1.  XDR-Klebsiella pneumoniae isolates harboring blaOXA-48: In vitro and in vivo evaluation using a murine thigh-infection model.

Authors:  Noha A Kamel; Wafaa N El-Tayeb; Mona R El-Ansary; Mohamed T Mansour; Khaled M Aboshanab
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-31

Review 2.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

3.  Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa.

Authors:  Yu-Wei Lin; Heidi H Yu; Jinxin Zhao; Mei-Ling Han; Yan Zhu; Jesmin Akter; Hasini Wickremasinghe; Hasini Walpola; Veronika Wirth; Gauri G Rao; Alan Forrest; Tony Velkov; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

4.  Pharmacodynamics and Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis.

Authors:  Michael A Lyons
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

5.  Semimechanistic Pharmacodynamic Modeling of Aztreonam-Avibactam Combination to Understand Its Antimicrobial Activity Against Multidrug-Resistant Gram-Negative Bacteria.

Authors:  Alexia Chauzy; Bruna Gaelzer Silva Torres; Julien Buyck; Boudewijn de Jonge; Christophe Adier; Sandrine Marchand; William Couet; Nicolas Grégoire
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-08-16

Review 6.  Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.

Authors:  Craig R Rayner; Patrick F Smith; David Andes; Kayla Andrews; Hartmut Derendorf; Lena E Friberg; Debra Hanna; Alex Lepak; Edward Mills; Thomas M Polasek; Jason A Roberts; Virna Schuck; Mark J Shelton; David Wesche; Karen Rowland-Yeo
Journal:  Clin Pharmacol Ther       Date:  2021-03-09       Impact factor: 6.875

Review 7.  The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials.

Authors:  Alicia Rodríguez-Gascón; María Ángeles Solinís; Arantxa Isla
Journal:  Pharmaceutics       Date:  2021-06-03       Impact factor: 6.321

8.  Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

Authors:  Frank Kloprogge; Robert Hammond; Andrew Copas; Stephen H Gillespie; Oscar Della Pasqua
Journal:  J Antimicrob Chemother       Date:  2019-12-01       Impact factor: 5.790

9.  In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris.

Authors:  Unai Caballero; Sarah Kim; Elena Eraso; Guillermo Quindós; Valvanera Vozmediano; Stephan Schmidt; Nerea Jauregizar
Journal:  Antibiotics (Basel)       Date:  2021-03-28

10.  Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin.

Authors:  Tomás Sou; Jon Hansen; Edgars Liepinsh; Maria Backlund; Onur Ercan; Solveiga Grinberga; Sha Cao; Paraskevi Giachou; Anna Petersson; Magdalena Tomczak; Malgorzata Urbas; Dorota Zabicka; Carina Vingsbo Lundberg; Diarmaid Hughes; Sven N Hobbie; Lena E Friberg
Journal:  Clin Pharmacol Ther       Date:  2020-11-28       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.